Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Memory impairment17.03.02.003; 19.20.01.003--
Mental disability26.01.01.001--Not Available
Mental impairment17.03.03.002; 19.21.02.003--Not Available
Micturition disorder20.02.02.0050.000041%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.0030.000580%Not Available
Mood swings19.04.03.001--Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Mydriasis06.05.03.004; 17.02.11.003--Not Available
Myelitis transverse17.06.02.002; 10.04.10.0060.000031%Not Available
Myelopathy17.10.01.0070.000083%Not Available
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Neonatal disorder18.04.01.0010.000021%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Night sweats23.02.03.006; 08.01.03.031--Not Available
Obsessive-compulsive disorder19.06.05.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophageal achalasia07.02.03.0040.000041%Not Available
Oesophageal obstruction07.13.02.0020.000021%
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 16 Pages